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Abstract
Background
The effectiveness of anti-parasite treatment with benznidazole in the chronic Chagas dis-
ease (ChD) remains uncertain. We evaluated, using data from the NIH-sponsored SaMi-
Trop prospective cohort study, if previous treatment with benznidazole is associated with
lower mortality, less advanced cardiac disease and lower parasitemia in patients with
chronic ChD.
Methods
The study enrolled 1,959 ChD patients and abnormal electrocardiogram (ECG) from in 21
remote towns in Brazil. A total of 1,813 patients were evaluated at baseline and after two
years of follow-up. Those who received at least one course of benznidazole were classified
as treated group (TrG = 493) and those who were never treated as control group (CG =
1,320). The primary outcome was death after two-year follow-up; the secondary outcomes
were presence at the baseline of major ChD-associated ECG abnormalities, NT-ProBNP
levels suggestive of heart failure, and PCR positivity.
Results
Mortality after two years was 6.3%; it was lower in the TrG (2.8%) than the CG (7.6%);
adjusted OR: 0.37 (95%CI: 0.21;0.63). The ECG abnormalities typical for ChD and high
age-adjusted NT-ProBNP levels suggestive of heart failure were lower in the TrG than the
CG, OR: 0.35 [CI: 0.23;0.53]. The TrG had significantly lower rates of PCR positivity, OR:
0.35 [CI: 0.27;0.45].
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Conclusion
Patients previously treated with benznidazole had significantly reduced parasitemia, a lower
prevalence of markers of severe cardiomyopathy, and lower mortality after two years of fol-
low-up. If used in the early phases, benznidazole treatment may improve clinical and parasi-
tological outcomes in patients with chronic ChD.
Trial registration
ClinicalTrials.gov, Trial registration: NCT02646943.
Author summary
Chagas disease remains as one of the most neglected infectious diseases of the world, with
millions of persons infected and dozens of thousands of deaths every year. The disease has
a very long natural history and few options of etiologic treatment, including antiparasitic
[1] drugs benznidazole and nifurtimox. Benznidazole has been recommended for treat-
ment of the disease based mostly in physiopathological assumptions and relatively small
observational studies and, recently, a negative trial was published, showing the absence of
benefit of benznidazole in patients with Chagas cardiopathy. Thus, there is an urgent need
not only of new therapeutic options but also of further evidence of the utility of benznida-
zole, at least in those patients with less severe disease. We conducted an observational
study in the NIH SaMi-Trop cohort comparing patients with self-reported previous treat-
ment with benznidazole with non-treated ones, using as primary outcome death in the
follow-up of 2 years, and as secondary outcomes markers of severity based in the ECG
and NT-proBNP levels, as well as parasitemia by PCR for Trypanosoma cruzi DNA in
blood. Patients previously treated with benznidazole had significantly reduced parasite-
mia, a lower frequency of markers of severe cardiomyopathy and reduced mortality. If
used in the early phases of Chagas disease, benznidazole treatment may result in better
clinical and parasitological outcomes. It is reasonable to consider treating all Chagas dis-
ease patients without advanced cardiopathy with benznidazole, especially those less than
50 years-old of age.
Introduction
Chagas disease (ChD), caused by the protozoa Trypanosoma cruzi, is one of the most impor-
tant neglected diseases and a leading cause of cardiopathy and death in Latin America, [1][2]
where it is endemic with an estimated 5.7 million infected people [3]. With continuing migra-
tion from Latin America to North America and Europe, ChD has become a global problem,
with hundreds of thousands of infected persons living in non-endemic countries [1]. Global
costs related to ChD are estimated at $7.19 billion per year, with a substantial proportion of
the burden resulting from lost productivity from cardiovascular disease-induced morbidity
and early mortality [4].
ChD has a very long natural history which begins that an acute phase, generally a benign
and self-limited febrile disease in childhood [2]. After remission of the acute manifestations,
most patients enter a chronic phase without clinical manifestations of the disease, the so-called
chronic indeterminate form of ChD, which can persist for decades or be lifelong, or can evolve
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into the cardiac or intestinal forms of the disease [1]. Chagas cardiomyopathy is the most seri-
ous manifestation of ChD and may present as heart failure, ventricular arrhythmias, heart
block, or thromboembolic phenomena [1]; ~2% of indeterminate form patients evolve to clini-
cally diagnosed cardiac disease each year [5]. The pathophysiological mechanisms underlying
and prognostic markers predicting progression to cardiomyopathy are poorly understood.
Two drugs with proven anti-parasite efficacy that are used to treat ChD patients are avail-
able: nifurtimox and benznidazole; most studies have focused on the use of benznidazole due
to its better tolerability, reduced toxicity and, possibly, enhanced efficacy [6]. In Brazil, only
BZN has been approved for commercialization. It treatment schedule recommended is
300mg/day for 60 consecutive days [7].
Although persistence of low-level systemic infection, including cardiac T. cruzi infection in
the indeterminate phase seems to play an important role in the development of Chagas cardio-
myopathy, the effectiveness of treatment during the chronic phase in preventing progression
of disease and in reducing mortality remains unclear [8] [9]. Indeed, although observational
studies have suggested that treating chronic ChD patients with benznidazole can lead to para-
site clearance reversion, and reduced progression of clinical manifestation [8] [10], the recently
published BENEFIT trial, a multicenter, randomized, double-blinded, placebo-controlled trial,
did not demonstrate a beneficial effect of benznidazole on cardiac outcomes in patients with
chronic Chagas cardiopathy [9]. The role of benznidazole in preventing the appearance of car-
diac lesions when used in less advanced disease is still controversial. In this observational
study, conducted in a large sample of Brazilian ChD patients, we evaluated if previous treat-
ment with benznidazole is associated with less advanced cardiac disease, lower prevalence of
detectable parasitemia and lower mortality, compared to untreated control patients with
chronic ChD.
Methods
Study design, population measurements and outcomes
SaMi-Trop is a prospective cohort study with two-year follow-up to date (recently funded to
continue follow-up), including one baseline visit and another visit at 24 months [11]. The
cohort was established with patients under the care of the Telehealth Network of Minas Gerais
(TNMG), a program designed to support primary care in Brazil [12]. In this publicly funded
program, all patients’ electrocardiograms (ECG) and clinical data are sent to a central reading
unit that also collects clinical data, such as the history of the diagnosis of ChD. Using the data-
base from 2011 and 2012, we selected 21 municipalities within a limited region in the northern
part of the State of Minas Gerais, where the prevalence of ChD is high. Patients who reported
having ChD at the time of their previous ECG examination in 2011 and 2012 were invited to
join this cohort.
For this investigation, we used two epidemiological study designs. The first was a cross-sec-
tional analysis using baseline SaMi-Trop data collected at recruitment time (2013–14) and the
second one was a prospective cohort analysis using only death as an outcome collected at the
end of two-year of follow-up (2015–16, see Fig 1).
The exposition was self-reported treatment with benznidazole, which occurred (or not) sev-
eral years before the recruitment for the study. The primary outcome was death from any
cause after two-year follow-up (2015–16). Secondary outcomes were all evaluated at baseline
of SaMi-Trop study (2013–14) and included the presence of typical ChD-associated ECG
abnormalities, age-adjusted brain-type natriuretic peptide (NT-ProBNP) levels suggestive of
heart failure, and polymerase-chain-reaction (PCR) positivity for T. cruzi DNA in blood. We
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also developed a composite outcome in which we combined ECG abnormalities typical for
ChD and age-adjusted NT-proBNP levels suggestive of heart failure.
At baseline, all consenting participants were interviewed, with detailed questions on the
duration and clinical manifestations of ChD and previous use of benznidazole, and blood was
collected for T. cruzi serology, PCR and NT-proBNP measurement. To confirm the self-dis-
closed ChD diagnosis, serum samples from all enrolled patients were tested for the presence of
anti-T. cruzi antibodies using a chemiluminescent microparticle immunoassay (Architect Cha-
gas, Abbott Laboratories, Wiesbaden Germany). Negative results were confirmed by two other
enzyme immunoassays (EIA) presenting different T. cruzi antigens (Chagatest v.4, Wiener and
Chagas, Diasorin). The final study population for the current analyses consisted only of
patients confirmed to be T. cruzi seropositive [11]. The target-capture (TC) real-time (RT)
PCR assay used in this study was developed based on the method described by Pyron et al.
[13]. Two replicate TC-PCR assays were performed and results interpreted as positive if both
were positive. If only one replicate result was positive, it was considered as inconclusive, and
another aliquot of this sample was processed in four replicates. The results were considered
positive if at least two of the four additional replicates were positive [14]. NT-proBNP (Roche
diagnostics) was categorized according to age-specific cut-points for heart failure [15] [16].
An ECG was also performed at the baseline visit. Although a report of an abnormal ECG
was considered for recruitment of patients using the telehealth database, 17% of these ECG did
not fulfill diagnostic criteria of the presence of an ECG abnormality after standardized central
reading. The resting 12-lead ECG was recorded using a PC-based ECG machine (TEB, São
Paulo, Brazil). The ECG recordings were sent electronically to the Telehealth system and the
ECG measurements were obtained through automated analysis using the University of Glas-
gow ECG analysis program (release 28.5, issued on January 2014) [17]. All ECGs were over-
read manually by an experienced cardiologist. It were classified using the Minnesota Code
(MC) criteria, with variables derived from the median complex of the Glasgow University soft-
ware measurement matrix [18]. ECG abnormalities considered typical of Chagas cardiomyop-
athy included [17]: complete intraventricular block (7.1, 7.2, 7.4 or 7.8), frequent ventricular
premature beats (MC 8.1.2 or 8.1.3), atrial fibrillation or flutter or supraventricular tachycardia
Fig 1. Study design diagram.
https://doi.org/10.1371/journal.pntd.0006814.g001
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(MC 8.3.x. or 8.4.2), other major arrhythmias (MC 8.2.x, except 8.2.1), major atrioventricular
conduction abnormalities or pacemaker use (MC 6.1, 6.2.x, 6.4, 6.8, 8.6.1 or 8.6.2), major Q-
wave abnormalities [MC 1.1.x or 1.2.x] or minor Q-waves abnormalities with ST segment or
T-wave abnormalities [1.3.x and 4.1.x, 4.2, 5.1 or 5.2], or major isolated ST segment or T-wave
abnormalities (MC 4.1.x, 4.2, 5.1 or 5.2).
Death during the 2-year follow-up period was ascertained for enrolled participants who
could not be contacted for their 2-year follow-up visit by interviewing family members and
reviewing death certificate data of the Mortality Information System database for the State of
Minas Gerais.
The simple size was calculated considering the minimal number of events per variable
acceptable in a proportional hazards regression analysis of 10 events per variable. For a 2-year
follow-up period and annual mortality rate of 5% in chronic Chagas cardiomyopathy (10% in
2 years), the calculated sample size was about 2000 participants [11].
Statistical analyses
ChD subjects who received at least one course of treatment with benznidazole were classified
as belonging to the treated group (TrG = 493) and those who were never treated as control
group (CG = 1,320). Patients who did not know whether they had been treated with benznida-
zole use were excluded from analysis (n = 146). In descriptive analyses, categorical variables
were presented as numbers and percentages, continuous variables were summarized as means
and standard deviations.
Three measures of treatment effectiveness were calculated. The first was an unadjusted
effect measure (difference of proportions, averages or odds ratio, depending on the outcome
being studied) using an unpaired t-test or Fisher’s exact test. The second comparison estimated
the treatment effect using linear or logistic regression, adjusted for sex, age, income, literacy,
duration of known ChD, and hypertension as covariates. The third approach was a pairing
method (Genetic Matching), an evolutionary algorithm that seeks to maximize the balance of
the distributions of the treated units and controls [19] [20], using the same covariates
described above. This method can be used as an approximation of a traditional clinical trial
and provides the basis to an inference of causality.
In the paired analysis (Genetic Matching), for the continuous outcomes, the standard test
of the Matching package was used by means of Abadie-Imbens estimator for the standard
error. Missing values in the covariates were treated by simple imputation; with this approach,
there was a loss of six observations. The level of significance was α = 0.05, and the hypothesis
tests were 2-sided. Analyzes were performed in R version 3.3.2 using GenMatch and Geepack
packages.
We performed Kaplan-Meier survival analysis and used the log-rank test to compare time
to death between treatment and control groups. Because the number of patients after two
years of follow-up was small, we censored the follow-up after this time.
Ethics statement
The study was conducted using data from the NIH-sponsored São Paulo-Minas Gerais Tropi-
cal Medicine Research Center (SaMi-Trop) study, established in a highly endemic region of
Brazil [11]. The protocol was approved by the Brazilian National Institutional Review Board
(CONEP), number 179.685/2012. In this investigation, all human subjects were adult whose
have given written informed consent. Participants had full right to continue or withdraw from
the study. The confidentiality of all participants was maintained throughout the study.
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Results
Study patients
This investigation was conducted on the 1,813 patients who were confirmed as being infected
with T. cruzi based on positive serology and who had information about benznidazole use,
from a total of 2157 patient who were enrolled in the SaMi-Trop cohort. Previous use of benz-
nidazole (TrG) was reported by 493 patients; the average duration of use was self-reported as
90 days. Most patients started treatment soon after their serological diagnosis of infection
(64% within 30 days, 20% between 1–12 months, and 16% after one year). A total of 83% of the
treated patients reported that were treated before having 40 years of age. The characteristics of
the patients according to treatment group are presented in Table 1.
The mean age was higher for the CG (CG: 59.1 years versus TrG: 54.1 years, P<0.01). Most
of the patients were female and the majority in both groups self-reported having been diag-
nosed with ChD for more than 10 years (TrG: 73.3% versus CG: 58.4%) before being inter-
viewed. In general, patients in the CG presented with worse clinical conditions, including
hypertension, diabetes mellitus, ECG typical of Chagas disease, NT-ProBNP levels suggestive
of heart failure and PCR positivity, as well as higher use of medications other than benznida-
zole (P<0.01), except Beta-blockers, ACE and ARA.
Primary and secondary outcomes
Adverse outcomes in the TrG unmatched-control (unadjusted or adjusted by linear or logistic
regression), and matched-control (genetic matching) analysis are presented in Table 2. All
reported adjusted odds ratios (OR) in this section used the genetic matching method, but
Table 1. Characteristics of the patients, by treatment and control group.
Characteristics Valid number Treatment
(n: 493)
Control
(n: 1320)
P-value
Age—mean (SD) 1813 54.1±11.5 59.4±12.5 <0.001
Female sex—n (%) 1813 337/493 (68.4) 893/1320 (67.7) 0.755
Illiterate—n (%) 1807 149/493 (30.2) 600/1314 (45.7) <0.001
Family monthly income—US$ 1306 370.87±203.04 417.39+209.56 <0.001
Duration of ChD > 10 yr—n (%) 1768 355/484 (73.3) 728/1284 (56.7) <0.001
Hypertension—n (%) 1813 280/493 (56.8) 852/1320 (64.5) <0.001
Diabetes mellitus—n (%) 1813 34/493 (6.9) 133/1320 (10.1) <0.001
Pacemaker—n (%) 1792 24/493 (5.0) 86/1299 (6.6) 0.291
Medication—n (%)
Diuretic 1790 195/487 (40.0) 670/1303 (51.4) <0.001
Digoxin 1795 22/487 (4.5) 104/1308 (8.0) <0.001
Amiodarone 1749 87/464 (18.8) 324/1283 (25.3) <0.001
Beta-blocker 1791 41/486 (8.4) 91/1305 (7.0) 0.210
ACE inhibitor 1790 128/487 (26.3) 381/1303 (29.2) 0.150
ARA 1791 125/487 (25.7) 373/1304 (28.6) 0.153
ECG typical ChD—n (%) 1779 233/491 (47.3) 773/1288 (60.0) <0.001
High age-adjusted NT-ProBNP n (%) 1810 30/492 (6.1) 175/1318 (13.3) <0.001
PCR positivity—n (%) 1813 82/493 (16.6) 481/1320 (36.4) <0.001
Mortality in 2-year follow-up 1813 14/493 (2.8) 100/1320 (7.6) <0.001
ACE = Angiotensin converting enzyme; ARA = angiotensin receptor antagonists; ECG = Electrocardiogram; NT-ProBNP = N-terminal of the prohormone brain
natriuretic peptide; PCR = Polymerase-chain-reaction.
https://doi.org/10.1371/journal.pntd.0006814.t001
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similar effect of treatment was observed using adjusted regression. Proportions or means of
key clinical and parasitological results at the index visit were lower in the TrG than in the CG
(P<0.01). The overall mortality after two years of follow-up in enrolled patients with positive
serology for ChD was 114/1,813 (6.3%). It was lower in the TrG (2.8%, 14/493) than in the CG
(7.6%, 100/1,320); adjusted OR: 0.37 (0.21,0.63), indicating protection against death in the
TrG. Survival differed significantly among treatment and control groups: patients treated with
benznidazole had better survival compared with those in the CG (P = 0.001, Fig 2).
The age-adjusted NT-proBNP levels were lower in the TrG (6.1%, 30/492) than in CG
(13.3%, 175/1,318), indicating an adjusted odds ratio was 0.41 (95%CI: 0.28; 0.60) in favor of
the TrG. The TrG had a lower frequency of patients with NT-proBNP levels, above age-
adjusted reference values (Table 2). Major ECG abnormalities typical of ChD were lower in
the TrG (48.4% versus 60.0%), yielding an adjusted OR of 0.64 (CI: 0.52; 0.79). The TrG had a
smaller proportion of worse combined adverse outcomes (ECG abnormalities typical of ChD
and age-adjusted NT-proBNP levels) than the CG: 5.0% (24/480) versus 12.6% (162/1286);
adjusted OR: 0.35 (CI: 0.23, 0.53). T. cruzi PCR was positive in blood samples from 16.6% of
TrG patients versus 36.4% of the CG patients, with an adjusted OR using GenMatch of 0.35
[CI: 0.27; 0.45].
Discussion
In this investigation, when comparing patients previously treated with benznidazole with simi-
lar controls, we observed a lower frequency of markers of ChD cardiomyopathy severity a
reduction in parasitemia and a significantly lower risk of mortality over a 2 years of follow-up
period. Our findings help clarify the controversy about the effectiveness of benznidazole in the
treatment of ChD, especially in the early chronic phase of the disease. Although there is an
urgent need for better therapies than can stop or delay the progression of ChD in millions of
infected persons around the world, [21] none of the new compounds tested for treating ChD
thus far has come close to the efficacy observed with benznidazole [22].
A significant reduction in parasitemia, as measured by PCR, in patients treated with benz-
nidazole has been reported in previous studies [10], including data from the REDS-2 study
[23] and the BENEFIT trial [9]. Benznidazole has also been shown to be superior to posacona-
zole and E1224, a new anti-parasite drug, in reduction of PCR positivity in ChD patients, as
recently shown in multicenter randomized placebo-controlled studies with parasitological
endpoints, with follow-up periods of 10 to 12 months [24] [25] [26]. Our data from a large
Table 2. General outcome in the treatment, unmatched and matched control groups.
Outcomes Treatment
% (n)
Control
% (n)
Univariate Multivariate
(Regression)
Genetic Matching
(matched analysis)
OR† (95% CI) OR (95% CI) OR (95% CI)
Mortality 2-year follow-up 2.8 (14/493) 7.6 (100/1320) 0.36 (0.19, 0.63) 0.42 (0.23, 0.76) 0.37 (0.21, 0.63)
High age-adjusted NT-ProBNP 6.1 (30/492) 13.3 (175/1318) 0.42 (0.27, 0.64) 0.41 (0.27, 0.63) 0.41 (0.28, 0.60)
ECG abnormalities typical ChD 48.4 (233/481) 60.0 (773/1288) 0.63 (0.50, 0.78) 0.67 (0.53, 0.84) 0.64 (0.52, 0.79)
ECG abnormalities typical ChD +
High age-adjusted NT-ProBNP
5.0 (24/480) 12.6 (162/1286) 0.37 (0.22, 0.57) 0.36 (0.23, 0.57) 0.35 (0.23, 0.53)
PCR positivity for T. cruzi DNA 16.6 (82/493) 36.4 (481/1320) 0.35 (0.26, 0.45) 0.35 (0.26, 0.46) 0.35 (0.27, 0.45)
NT-ProBNP = N-terminal of the prohormone brain natriuretic peptide; ECG = Electrocardiogram; ChD = Chagas disease; PCR = Polymerase-chain-reaction.
 Adjusted by age, gender, literate, duration of ChD, family monthly income and hypertension.
†Odds ratio
https://doi.org/10.1371/journal.pntd.0006814.t002
Beneficial effects of benznidazole in Chagas disease
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006814 November 1, 2018 7 / 12
population in which most patients had been treated more than 10 years ago extends previous
observations, as we show that PCR positivity for T. cruzi was twice in untreated patients as
compared with treated ones, suggesting that benzonidazole induces a long-lasting clearance of
parasitemia.
The most important contribution of the present work is our demonstration of a marked
clinical benefit from benznidazole, including a reduction in well-established markers of ChD
severity, such as typical ECG abnormalities, high NT-proBNP levels or both, as well as mortal-
ity during the two years of follow-up after recruitment. The presence of typical or major ECG
abnormalities is an important marker of risk in Chagas disease [27] and marks the transition
from the indeterminate to the cardiac form of the disease [1]. Viotti et al [28] and Fragata-
Filho et al. [8] reported that treatment with benznidazole reduced the appearance of new ECG
abnormalities in a long-term follow-up study. However, a meta-analysis published recently
showed that this prevention of progression to cardiopathy was not significant when three
smaller observational studies were jointly analyzed [10]. Furthermore, in the BENEFIT study,
Fig 2. Kaplan-Meier survival curves in ChD by treatment and control group.
https://doi.org/10.1371/journal.pntd.0006814.g002
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in which 94% patients had an abnormal ECG at baseline, the rate of development of new ECG
abnormalities was the same in the treated and untreated groups [9].
Our results are further reinforced by the effect of previous treatment on NT-proBNP levels,
as those who were treated with benznidazole had a significantly lower frequency of high age-
adjusted levels than those who were untreated, both when NT-proBNP levels were considered
as a single outcome or in association with presence of typical ECG findings. Indeed, high levels
of BNP or NT-proBNP are an accurate marker of the presence of left ventricular systolic dys-
function [29] 6 and a strong prognostic marker in ChD patients [30]. The concomitance of
typical ECG abnormalities and high NT-proBNP levels identifies a subgroup of patients with
Chagas cardiopathy and left ventricular dysfunction, which is the group at highest risk of
death. Thus, it is highly relevant that previous treatment with benznidazole is associated with a
lower frequency of this composite outcome, which is itself a marker of an increased risk of
death.
The SaMi-Trop study is the first to show that previous treatment with benznidazole is asso-
ciated with a reduced risk of death in ChD. Viotti et. al observed a non-significant reduction
in the rate of death in the treated group [28], but the study was too small to allow any conclu-
sion about the beneficial effect of benznidazole in the risk of death. In the BENEFIT trial [9],
there was no difference in the mortality rate between treated and untreated groups. Since 83%
of the treated patients reported that the treatment occurred 10 years before the baseline eval-
uation, most patients in the cohort were treated before having 40 years of age, probably in an
early stage of the development of the disease. In contrast, those recruited for the BENEFIT trial
were, on average 55 years, of age and had well-established cardiomyopathy at the time treat-
ment. These differences suggest that effectiveness of the benznidazole in preventing progres-
sion of cardiomyopathy and death related to ChD is dependent on the stage of the disease and
the age of the patient when the treatment is initiated, which may help overcome reluctance
about the use of benzonidazole in patients with earlier stages of the disease who are less than
50 years of age.
The present study had limitations. We do not have reliable information about the dose of
trypanocidal drug or about the exact duration of treatment, as most patients used the drug
more than 10 years before the study interview. In this manuscript as the duration of treatment
was self-reported, we believe in memory bias, considering the long time between exposure and
interview to collect precision information. However, because benznidazole usage is a very spe-
cific event in the life of a ChD patient, we believe that most patients accurately recalled the
prior use of this medication as Yes/No. Moreover, we cannot assure that patients who received
benznidazole had the same clinical profiles as those who did not receive treatment. If those
treated had an average, milder disease than those who were untreated, our results could have
been biased in favor of treatment effect. This limitation is inherent to the study design,
although it is likely that, more than 10 years ago, when the treatment decisions were made,
most patients would have had milder forms of the disease. Additionally, those with severe car-
diopathy (at the time of the decision of treatment or not) probably did not survived the recruit-
ment period, considering the ominous prognosis of severe Chagas cardiomyopathy. The
imbalance in various features among the groups, typical of all observational studies, was at
least partly corrected by the method of matching used in this study, as confirmed by the multi-
variate analysis.
In Brazil, the transmission of ChD by Triatoma Infestans is eradicated, with certification
issued by the WHO in 2006. This certification is result of systematized disease control actions,
structured in Brazil in 1975 [31]. Although the transmission of the disease by Triatoma Infes-
tans vector is eradicated, secondary triatomines persist in the nature and can take place of the
eliminated species and transmit ChD. Thus, we cannot guarantee that patients treated with
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BZN have not been reinfected, however, so far, no vector transmission has been identified
after WHO certification. Brazil is currently in the surveillance phase, which includes the par-
ticipation of the population in the notification of triatomines identified in the households.
This notification is made to Triatomine Information Centers implanted in areas with a higher
risk of reinfestation [32]
Among the strengths of the study were the large sample of ChD patients living in an
endemic area, in contrast to other studies that had smaller numbers of patients from special-
ized clinics in large urban centers. Outcomes were measured in a reliable manner that effec-
tively reflects the clinical conditions of all patients, as well as their parasitological status. The
Genetic Matching applied in the statistical analysis is used as an approximation to traditional
clinical trial for inference of causality, and its results were confirmed by traditional regression
methods. Problems of regional heterogeneity of T. cruzi strains and uneven access to health
system, sometimes important in other studies, are not an issue in our study, as all patients
came from the same region, with similar limited access to health care services. Finally, our
results are robust, as a positive and strong effect in the treated group was observed in all clini-
cal and parasitological outcomes.
In conclusion, if used in the early phases of the disease, benznidazole treatment may result
in better clinical and parasitological outcomes. Because there are millions of untreated ChD
patients in the world and no new treatments are available for the foreseeable future, it is rea-
sonable to consider treating all Chagas disease patients without advanced cardiopathy with
benznidazole, especially those who are less than 50 years of age.
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